4.6 Article

Short-term venoarterial extracorporeal membrane oxygenation for massive endobronchial hemorrhage after pulmonary endarterectomy

期刊

出版社

MOSBY-ELSEVIER
DOI: 10.1016/j.jtcvs.2017.09.045

关键词

CTEPH; pulmonary endarterectomy; ECMO; endobronchial hemorrhage

资金

  1. Actelion
  2. Bayer
  3. Pfizer
  4. GSK
  5. Merck
  6. Novartis
  7. Takeda Pharmaceuticals
  8. Eli Lilly
  9. Bellerophon
  10. Pulse Technologies
  11. MSD
  12. BTG
  13. Mundipharma
  14. OMT
  15. Roche
  16. United Therapeutics

向作者/读者索取更多资源

Objectives: Pulmonary endarterectomy (PEA) is the only curative treatment option for patients with chronic thromboembolic pulmonary hypertension. Massive endobronchial bleeding that precludes weaning from cardiopulmonary bypass is an often-fatal complication of PEA. The aim of this study was to determine whether short-term extracorporeal membrane oxygenation (ECMO) is a safe and feasible procedure in patients with severe endobronchial bleeding. Methods: From January 2014 to December 2016, 396 patients (mean age 60 +/- 18 years, 54.5% male) underwent PEA in our department. Patients with severe endobronchial hemorrhage at the time of weaning from cardiopulmonary bypass (CPB) were switched to a heparin-coated venoarterial ECMO circuit. After full-dose protamine administration to restore normal coagulation, weaning from ECMO was attempted in the operating room. Results: In-hospital mortality was 2.3% (9/396 patients). Eight patients (2.0%) developed severe endobronchial bleeding classified as diffuse (n = 6) or localized (n = 2) by bronchoscopy. After reinstitution of CPB and subsequent switch to ECMO, the mean duration of ECMO support was 49 +/- 13 minutes, and all 8 patients were weaned successfully from ECMO in the operating theater without further signs of endobronchial bleeding. One patient needed venovenous ECMO support for poor oxygenation 6 hours after surgery. Seven patients were discharged after a prolonged postoperative stay of 17.6 +/- 4.1 days. One patient died. This new concept significantly reduced mortality compared with previous (2009-2013) ECMO support (P =.0406). Conclusions: For patients with massive endobronchial bleeding after PEA, the intraoperative switch from CPB to venoarterial ECMO support with full-dose protamine administration is a new and potentially life-saving treatment concept.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据